ProCE Banner Activity

Phase III EMPOWER-Lung 1 Subgroup Analysis: First-line Cemiplimab vs Chemotherapy in Patients With Locally Advanced NSCLC With PD-L1 ≥50%

Slideset Download
Conference Coverage
In this post hoc subgroup analysis, first-line cemiplimab significantly improved PFS and numerically improved OS and ORR vs platinum-based chemotherapy in patients with locally advanced NSCLC and PD-L1 ≥50% who were ineligible for definitive concurrent chemoradiotherapy or had recurrence after concurrent chemoradiotherapy.

Released: September 16, 2021

Expiration: September 15, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme